Stay updated with breaking news from Leyden Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leyden Laboratories B.V., (the "Company" or "Leyden Labs") announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114. CR9114 is
Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of... | November 14, 2022
Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of... | May 13, 2022
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.